[1] |
LI Hongchang, GE Yunxuan, WANG Ningning, ZHOU Wei, WANG Yuguang, MA Zengchun, GAO Yue.
Research progress in roles of ginseng combined with Radix Aconiti Carmichaeli in reducing toxicity and increasing efficiency in myocardial cells
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 601-605.
|
[2] |
PAN Zhiyu, ZHU Jian, YU Yanan, LIU Jun, JIANG Yanhua, QIAN Zhenzhen, WU Guang, WANG Zhong, WU Hongli, JING Zhiwei.
A real-world safety study of 3 010 cases of Qizhitongluo capsule
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 660-665.
|
[3] |
SHAO Bo, XU Lili, ZHU Lan, LIU Shuo, WAN Hao, HUANG Guangrui.
Risks of liver injury caused by Shiduqing preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 666-670.
|
[4] |
GAO Xu, PENG Jin’e, FAN Zibo, ZHANG Wei.
Systematic evaluation of clinical features and prognostic outcomes of rifampicin-induced hemolytic anemia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 671-676.
|
[5] |
ALATENG Hua, GAO Lei, ZHANG Xiaomeng, ZHANG Bing.
Exploring the scientific connotation of Mongolian Medicine pharmacovigilance based on ancient Mongolian Medical literature
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 677-682.
|
[6] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
[7] |
SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang.
Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
|
[8] |
LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan.
Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.
|
[9] |
TANG Zhenju, LONG Xiaohuan, WANG Yijun, HUANG Yuteng, WANG Weiliang.
One case of erythema multiforme drug eruption caused by donafenib tosilate tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 700-702.
|
[10] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
[11] |
QIN Jiaqi, ZHANG Fan, LYU Dongxia, HE Zhen, WEI Yuhui.
Functions of PXR/CAR-metabolizing enzyme/transporter detoxification system and research progress
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 709-715.
|
[12] |
ZHAO Xiaolu, GAO Xiaoyang, ZHANG Chunyan, LI Mingqi, MA Yuehong.
Effect of PPARγ in liver fibrosis and current development of its ligand drugs: research progress
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 716-720.
|
[13] |
GAO Haiyun, LI Yao, CHEN Yuxin, LI Hui, LIU Tianrui, YUAN Yuan.
Research progress in pharmacology and safe use of Boletus edulis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 507-512.
|
[14] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[15] |
LI Wenpeng, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Applications and progress of methods for estimating opioids requirements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 519-523.
|